WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Head of Health Policy and Programs of the Biotechnology Innovation Organization (BIO) released the following statement on the December ...

WASHINGTON, DC (December 2, 2025) – The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released today its latest biennial report ...

How the BIO IP Conference moved the conversation forward. Also, patient perspectives on diabetes innovation. (761 words, 3 minutes, 48 seconds) BIO IP Conference covers present and future of patent ...

WASHINGTON, D.C. – The Biotechnology Innovation Organization (BIO) released the following statement on today’s passage of the Mikaela Naylon Give Kids a Chance Act in the House of Representatives.

Since Watson and Crick discovered DNA's double helix structure in 1953, the US has been a leader in biotechnology innovation. American excellence in this field has greatly benefited people around the ...

Every year, JPM Healthcare Week sets the pace for biotech deal-making. But the skills and insights you gain from preparing for high stakes partnering meetings are valuable long after January. In this ...

It's been a busy week at BIO's IP Conference – here's what we've learned so far. (735 words, 3 minutes, 40 seconds) BIO IP Conference: Patent experts discuss changing times Leading experts in ...

Happy Thanksgiving week! We're covering a vaccine falsehood from CDC and the need for policy to address AMR. (692 words, 3 minutes, 27 seconds) CDC statement on autism and vaccines draws wide ...

We’re heading to Southern California to cover the BIO IP Conference—and why biotech needs strong patents. Here’s what we’re watching, plus a recap of BIO on the American Road in Indiana. (853 words, 4 ...

•The FDA is undergoing a strategic reevaluation of its policies under new leadership, prompted by rapid advancements in science and technology. •Now is the time for FDA to pursue a proactive policy ...

Theodore is an intellectual Property attorney with 20+ years of experience protecting innovation and building patent portfolios, including preparing and executing strategic intellectual property plans ...

Jane Xia is an Assistant General Counsel Patents at Johnson & Johnson, specializing in patent strategy, portfolio development, licensing, and IP-related transactions. With over 13 years of experience, ...